131 related articles for article (PubMed ID: 16215959)
1. The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors.
de Chastonay J
J Pept Sci; 2005 Nov; 11(11):754-5. PubMed ID: 16215959
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing peptides as active pharmaceutical ingredients.
Zompra AA; Galanis AS; Werbitzky O; Albericio F
Future Med Chem; 2009 May; 1(2):361-77. PubMed ID: 21425973
[TBL] [Abstract][Full Text] [Related]
4. Synthetic therapeutic peptides: science and market.
Vlieghe P; Lisowski V; Martinez J; Khrestchatisky M
Drug Discov Today; 2010 Jan; 15(1-2):40-56. PubMed ID: 19879957
[TBL] [Abstract][Full Text] [Related]
5. Current trends in the clinical development of peptide therapeutics.
Saladin PM; Zhang BD; Reichert JM
IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221
[TBL] [Abstract][Full Text] [Related]
6. [Drug flow. Good manufacturing practices, good clinical practices].
Dupin-Spriet T; Spriet A
Therapie; 1991; 46(1):69-74. PubMed ID: 2020929
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical GMP: past, present, and future--a review.
Patel KT; Chotai NP
Pharmazie; 2008 Apr; 63(4):251-5. PubMed ID: 18468382
[TBL] [Abstract][Full Text] [Related]
8. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides.
Agyei D; Danquah MK
Biotechnol Adv; 2011; 29(3):272-7. PubMed ID: 21238564
[TBL] [Abstract][Full Text] [Related]
9. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
10. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
11. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
Woo J; Wolfgang S; Batista H
Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
[TBL] [Abstract][Full Text] [Related]
12. Advances in automatic, manual and microwave-assisted solid-phase peptide synthesis.
Sabatino G; Papini AM
Curr Opin Drug Discov Devel; 2008 Nov; 11(6):762-70. PubMed ID: 18946841
[TBL] [Abstract][Full Text] [Related]
13. Peptide-based drug design: here and now.
Otvos L
Methods Mol Biol; 2008; 494():1-8. PubMed ID: 18726565
[TBL] [Abstract][Full Text] [Related]
14. Symposium review: drug discovery, development and clinical research in academia.
Vlaar CP; Hernández L
P R Health Sci J; 2009 Sep; 28(3):268-73. PubMed ID: 19715120
[TBL] [Abstract][Full Text] [Related]
15. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
[TBL] [Abstract][Full Text] [Related]
16. Prediction of activity, synthesis and biological testing of anti-HSV active peptides.
Jenssen H; Gutteberg TJ; Rekdal Ø; Lejon T
Chem Biol Drug Des; 2006 Jul; 68(1):58-66. PubMed ID: 16923027
[TBL] [Abstract][Full Text] [Related]
17. The state of innovation in drug development.
Kola I
Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
[TBL] [Abstract][Full Text] [Related]
18. The relationship between paediatricians and commerce.
Hilliard T; Chambers T
Paediatr Respir Rev; 2006 Mar; 7(1):54-9. PubMed ID: 16473818
[TBL] [Abstract][Full Text] [Related]
19. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
Peppercorn J; Blood E; Winer E; Partridge A
Cancer; 2007 Apr; 109(7):1239-46. PubMed ID: 17326054
[TBL] [Abstract][Full Text] [Related]
20. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
